Evvy develops at-home vaginal microbiome tests using metagenomic sequencing to understand symptoms and risks for critical health challenges.
Evvy has raised $14.0M in total funding. The most recent round was Series A. The last funding was announced in September 2023.
Evvy's investors include General Catalyst, BoxGroup, Human Ventures, Virtue, Left Lane Capital.
Evvy is headquartered in New York, United States.
Evvy develops at-home vaginal microbiome tests using metagenomic sequencing to understand symptoms and risks for critical health challenges.
Evvy is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Evvy — Funding & Investors." VCBacked, September 27, 2023, https://www.vcbacked.co/company/evvy. Accessed July 19, 2026.
VCBacked. (2023). Evvy — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/evvy
{{cite web |title=Evvy — Funding & Investors |url=https://www.vcbacked.co/company/evvy |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated